<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/23454317-ADC4-4369-A212-BF0802191E59"><gtr:id>23454317-ADC4-4369-A212-BF0802191E59</gtr:id><gtr:name>Domainex</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F7CB3F0-F626-4D76-9C43-28FB0DB6A61C"><gtr:id>2F7CB3F0-F626-4D76-9C43-28FB0DB6A61C</gtr:id><gtr:name>Takeda Pharmaceutical Company</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/517D56CB-2E67-4945-B0A5-37E7F81A865A"><gtr:id>517D56CB-2E67-4945-B0A5-37E7F81A865A</gtr:id><gtr:name>Takeda Cambridge Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/07883787-C252-44BB-81D1-81AECF29A9A1"><gtr:id>07883787-C252-44BB-81D1-81AECF29A9A1</gtr:id><gtr:name>Diamond Light Source</gtr:name><gtr:address><gtr:line1>Diamond House</gtr:line1><gtr:line2>Harwell Science and Innovation Camp</gtr:line2><gtr:line3>Didcot</gtr:line3><gtr:line4>Oxfordshire</gtr:line4><gtr:postCode>OX11 0DE</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Sch of Chemistry</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/23454317-ADC4-4369-A212-BF0802191E59"><gtr:id>23454317-ADC4-4369-A212-BF0802191E59</gtr:id><gtr:name>Domainex</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F7CB3F0-F626-4D76-9C43-28FB0DB6A61C"><gtr:id>2F7CB3F0-F626-4D76-9C43-28FB0DB6A61C</gtr:id><gtr:name>Takeda Pharmaceutical Company</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/517D56CB-2E67-4945-B0A5-37E7F81A865A"><gtr:id>517D56CB-2E67-4945-B0A5-37E7F81A865A</gtr:id><gtr:name>Takeda Cambridge Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/07883787-C252-44BB-81D1-81AECF29A9A1"><gtr:id>07883787-C252-44BB-81D1-81AECF29A9A1</gtr:id><gtr:name>Diamond Light Source</gtr:name><gtr:address><gtr:line1>Diamond House</gtr:line1><gtr:line2>Harwell Science and Innovation Camp</gtr:line2><gtr:line3>Didcot</gtr:line3><gtr:line4>Oxfordshire</gtr:line4><gtr:postCode>OX11 0DE</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DF0020F8-9212-4670-ADC0-CBDFF5B93548"><gtr:id>DF0020F8-9212-4670-ADC0-CBDFF5B93548</gtr:id><gtr:name>GlaxoSmithKline</gtr:name><gtr:address><gtr:line1>Stockley Park West</gtr:line1><gtr:line4>Uxbridge</gtr:line4><gtr:postCode>UB11 1BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C272821C-43F3-4F25-B3EE-115F04688C2F"><gtr:id>C272821C-43F3-4F25-B3EE-115F04688C2F</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Philip</gtr:otherNames><gtr:surname>Marsden</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D5EFBF0C-D6EC-48B1-B5C8-D211482E7B44"><gtr:id>D5EFBF0C-D6EC-48B1-B5C8-D211482E7B44</gtr:id><gtr:firstName>Adam</gtr:firstName><gtr:otherNames>Stephen</gtr:otherNames><gtr:surname>Nelson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FJ00894X%2F1"><gtr:id>41CBA34A-B53B-4657-9B4A-759FB383E559</gtr:id><gtr:title>Realising lead-oriented synthesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/J00894X/1</gtr:grantReference><gtr:abstractText>The pharmaceutical industry is the UK's third largest exporting sector, annually contributing &amp;pound;17bn to exports, and investing &amp;pound;4.5bn in UK research and development. The pharmaceutical industry is, however, dogged by a high failure rate (around 97%) of drug candidates, often late in the drug discovery process. A reduction in the failure rate of drug candidates would revolutionise the pharmaceutical industry (for example, a reduction in the rate of failure to even 94% would double the number of successful drugs).

The drug discovery process often begins with the screening of many (typically at least hundreds of thousands) molecules for a required biological function. Unfortunately, the active molecules identified in the high-throughput screening process are not optimised drug molecules; instead, these molecules (known as &amp;quot;leads&amp;quot;) are starting points for optimisation to give final drug molecules.

There is now a clear link between the physical properties of drug candidates and their probability of successfully negotiating the development process to yield marketed medicines. In turn, the properties of drug candidates are often dependent on those of lead molecules. Unfortunately, enhancement of corporate screening collections of molecules is hampered by the poor availability of large numbers of compounds with appropriate lead-like physical properties. A recent analysis of 4.6 million commercially available compounds revealed that less than 1% had optimal lead-like properties. Furthermore, emerging synthetic methods are not, in large part, addressing this deficiency: in 2009 papers in key synthetic organic chemistry journals, only 1.8% of prepared compounds (249 from 13454) had lead-like properties. The development of robust synthetic methods for preparing diverse and novel lead-like molecules remains a significant and unmet academic challenge.

This project will realise a new approach to synthetic chemistry - lead-oriented synthesis - which will focus on the preration of large numbers of diverse small molecules with lead-like physical properties. The project will specifically focus on the development of a systematic approach to the synthesis of diverse families of novel molecular scaffolds with designed 'lead-like' properties. Crucially, specific methods will only be optimised when it has been established that the requirements of lead-oriented synthesis are directly addressed. The project will involve the identification, optimisation and demonstration of the power of a toolkit of reactions that enable the synthesis of large numbers of diverse, lead-like molecules. 

Realising the full value of the research will require not only the successful execution of the approach, but the definition of a mechanism by which the technology can be made commercially available to end-users (in the pharmaceutical, and other discovery-based, industries). We have engaged, and will continue to engage, with end-users to ensure that the outputs of the project meet their specific requirements. The systematic approach will address the poor availability of lead-like compounds to end-users; will improve the physical properties of starting points and, hence, drug candidates; and will increase the probability of drug candidates negotiating the development process to become marketed medicines.</gtr:abstractText><gtr:potentialImpactText>The pathway to impact of the overall project will focus on (a) the definition of a pathway to commercialisation; (b) dissemination to industrial and academic scientists; and (c) improving the public's understanding of the importance of the underlying science. The investigators have a strong record of industrial engagement through collaborative studentships, EPSRC grant partnership, secondments, dissemination at leactures in industry and at conferences with industrial delegates, and leadership within RCUK-funded networks; in addition, the investigators have a strong track record of engagement with the public eg through talks at schools and education conferences; podcasts; and catalysing media up-take of their research outputs through press releases coinciding with high-impact publications.

1. Pathway to commercialisation
The proposal describes a systematic approach to generating diverse families of molecular scaffolds with designed 'lead-like' properties, addressing a demonstrated need within the pharmaceutical (and other discovery-based) industry. Realising the full value of the research will require not only the successful execution of the approach, but the definition of a mechanism by which the technology can be made commercially available to end-users. The definition of a viable mechanism will involve close working from the commencement of the project with the University of Leeds' Research and Innovation office, and Techtran (a subsidiary of IP Group PLC) that provides commercialisation services to the University of Leeds. Activities will include market assessment, protection of IP, and engagement with end-users at key stages within the project, and will lead to the identification of an effective means to bring novel, lead-like scaffolds to the market. We have requested specific funding for the time of an experienced, dedicated EKT manager (from the UoL Enterprise and Innovation Office) for market assessment and management of pathway to commericalisation (5% over 2 years). 

2. Dissemination
The research will be disseminated through publication in international, peer-reviewed journals following, where appropriate, protection of IP. Funds for publications have been requested (especially for colour figures which will be required to disseminate the research effectively).

3. Public understanding of science
Nelson and the postdoctoral researchers will prepare a podcast focusing on how the project has developed new synthetic chemistry that meets the specific requirements of the pharmaceutical industry. The podcast will be uploaded to appropriate websites to allow global dissemination, and will be targeted to AS/A2 Chemistry teachers as part of a project led by Dr Annette Taylor (Schools Liaison, School of Chemistry, University of Leeds). The investigators will work closely with the University of Leeds Press Office and GSK to continue to issue press releases to coincide with high-impact publications, and will continue to engage with the general public (eg through invited visits to schools; education conferences; Caf&amp;eacute; Scientifique, Headingley, Leeds). We have requested specific funding for public communication training (for the investigators and the PDRAs) and for the preparation of the podcast.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-04-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2012-04-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>533045</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Domainex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PPIs</gtr:description><gtr:id>60BD34C7-435E-4CF5-971E-596EB4E2ADA0</gtr:id><gtr:impact>N/A- only just started</gtr:impact><gtr:outcomeId>56b0e024256a09.85996593-2</gtr:outcomeId><gtr:partnerContribution>Expertise, assays, other assets, collaboration, secondments</gtr:partnerContribution><gtr:piContribution>Leeds is leading an EPSRC programme grant on protein-protein interactions that involves AstraZeneca, Domainex and Northern Institute for Cancer Research</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Takeda Cambridge Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Takeda</gtr:description><gtr:id>7941002D-0FDF-4924-A4D2-46C330C92B24</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>545b5063d64953.76781771-1</gtr:outcomeId><gtr:partnerContribution>Supervision. Input to project</gtr:partnerContribution><gtr:piContribution>Development of CNS scaffolds</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>Top down approach to molecular scaffolds</gtr:description><gtr:id>9B1DAFD2-271B-4422-B637-9D8DE44FA627</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>589af4488ed302.21695454-1</gtr:outcomeId><gtr:partnerContribution>Alignment with end-user need</gtr:partnerContribution><gtr:piContribution>Development of routes to diverse molecular scaffolds</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Takeda Pharmaceutical Company</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Takeda Global Research &amp; Development Centre (Europe)</gtr:department><gtr:description>Scaffolds for CNS drug discovery</gtr:description><gtr:id>53C20DD5-385F-4E51-A158-DD08DE832839</gtr:id><gtr:impact>A computational tool for assessing CNS scaffolds, and syntheses of prioritised scaffolds (described in Drug Discovery Today paper aimed at end-users)</gtr:impact><gtr:outcomeId>589af35e27c820.98439994-1</gtr:outcomeId><gtr:partnerContribution>Ensuring alignment with end-user need</gtr:partnerContribution><gtr:piContribution>Developed approaches for assessing, designing and preparing scaffolds for CNS drug discovery</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>AstraZeneca scaffolds</gtr:description><gtr:id>60D028B0-B080-4AA4-867F-7ED39D4B1318</gtr:id><gtr:impact>Two papers.</gtr:impact><gtr:outcomeId>545b4f15c96f93.28921222-1</gtr:outcomeId><gtr:partnerContribution>input into project</gtr:partnerContribution><gtr:piContribution>Developing of new approaches to molecular scaffolds</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PPIs</gtr:description><gtr:id>EB59FE31-EBD4-4CDA-83FE-1C86727A187B</gtr:id><gtr:impact>N/A- only just started</gtr:impact><gtr:outcomeId>56b0e024256a09.85996593-1</gtr:outcomeId><gtr:partnerContribution>Expertise, assays, other assets, collaboration, secondments</gtr:partnerContribution><gtr:piContribution>Leeds is leading an EPSRC programme grant on protein-protein interactions that involves AstraZeneca, Domainex and Northern Institute for Cancer Research</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Diamond Light Source</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Diamond</gtr:department><gtr:description>X-ray crystallographic fragment screening</gtr:description><gtr:id>607BDAD2-1B25-4511-8F11-53C6B65A35E4</gtr:id><gtr:impact>Fragment hits against epigenetic protein targets (output currently underreview)</gtr:impact><gtr:outcomeId>589af4bfe00445.84857742-1</gtr:outcomeId><gtr:partnerContribution>We provided fragments which were screened against targets at Diamond</gtr:partnerContribution><gtr:piContribution>Access to high-throughput XCHEM facility</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PPIs</gtr:description><gtr:id>DEC3103D-9BB0-4888-9D40-B819C11FB34B</gtr:id><gtr:impact>N/A- only just started</gtr:impact><gtr:outcomeId>56b0e024256a09.85996593-3</gtr:outcomeId><gtr:partnerContribution>Expertise, assays, other assets, collaboration, secondments</gtr:partnerContribution><gtr:piContribution>Leeds is leading an EPSRC programme grant on protein-protein interactions that involves AstraZeneca, Domainex and Northern Institute for Cancer Research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute for Molecular Physiology</gtr:department><gtr:description>MPI</gtr:description><gtr:id>FB547078-DF9A-4472-82AD-98DB13A66595</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>545b511215fa94.76061667-1</gtr:outcomeId><gtr:partnerContribution>HT screening and follow-up biology</gtr:partnerContribution><gtr:piContribution>Screening compounds</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>IMI European Lead Factory</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>European Molecular Biology Organisation</gtr:fundingOrg><gtr:id>DAA01A20-7073-4567-90F9-2AE5827BD0CE</gtr:id><gtr:outcomeId>545b52e2704ab0.23589184</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>570000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC responsive mode</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/P016618/1</gtr:fundingRef><gtr:id>25233E88-E41F-4971-8B1A-6D3B781BEA2A</gtr:id><gtr:outcomeId>589af56e2841b4.49653511</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC programme grant</gtr:description><gtr:end>2021-01-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/N013573/1</gtr:fundingRef><gtr:id>4C0536E1-F9A4-42A1-A614-82DF191B06B0</gtr:id><gtr:outcomeId>56b0e0c186f0a6.70148885</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Development of practical syntheses of a range of lead-like molecular scaffolds that aligned with the needs of high-throughput screening collections for the pharmaceutical industry</gtr:description><gtr:grantRef>EP/J00894X/1</gtr:grantRef><gtr:id>D7B0B7DD-8204-47BA-BFE8-C9196D2574F0</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>545b56a3603f54.77779107</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Syntheses of lead-like scaffolds</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>Synthetic methods for preparing diverse lead-like scaffolds. An open access computational tool (LLAMA) is available for the community to assess the lead-likeness of their scaffolds</gtr:description><gtr:exploitationPathways>An open access computational tool (LLAMA) is available for the community to assess the lead-likeness of their scaffolds</gtr:exploitationPathways><gtr:id>3A9A6726-48B5-41A4-B451-CD45C4D7157D</gtr:id><gtr:outcomeId>56c2ecc02008b4.74189737</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>https://llama.leeds.ac.uk</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>An open access computational tool for assessing the lead-likeness of molecular scaffolds</gtr:description><gtr:id>808DD52D-16A2-464A-ACE5-4B4AD7C8A274</gtr:id><gtr:impact>Used by about 300 chemists in industry and internationally. Used in teaching at Leeds and elsewhere</gtr:impact><gtr:outcomeId>56b1da393068d7.27325229</gtr:outcomeId><gtr:title>LLAMA</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:url>https://llama.leeds.ac.uk</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>100CEB66-824D-4513-B45F-3033CC7D72FF</gtr:id><gtr:title>A modular lead-oriented synthesis of diverse piperazine, 1,4-diazepane and 1,5-diazocane scaffolds.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec0dac6bfc1423c88ef584192aba005c"><gtr:id>ec0dac6bfc1423c88ef584192aba005c</gtr:id><gtr:otherNames>James T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>545b4383adedf7.43680310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03A04BF1-0812-405C-AA1A-2CFA9B62E5EB</gtr:id><gtr:title>Recent advances and applications of iridium-catalysed asymmetric allylic substitution.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ea70a32e0d95d95ab913ae93e474cd0"><gtr:id>3ea70a32e0d95d95ab913ae93e474cd0</gtr:id><gtr:otherNames>Tosatti P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>545b4384c58bb0.65134347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DF3B4D1-ACD8-4A1E-B1F5-D0CD0B242623</gtr:id><gtr:title>Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/424a7ef00cd6a71619e9ecbf1032c8b1"><gtr:id>424a7ef00cd6a71619e9ecbf1032c8b1</gtr:id><gtr:otherNames>Karawajczyk A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>56b0deda86baa5.56976290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8581DFC-C981-4CC1-AEBC-E6DC4398AFEB</gtr:id><gtr:title>Modular synthesis of thirty lead-like scaffolds suitable for CNS drug discovery.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94f9ec979a8e4e2d32d150b974baf259"><gtr:id>94f9ec979a8e4e2d32d150b974baf259</gtr:id><gtr:otherNames>Mayol-Llin?s J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>5a2fed70f39455.52942583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15CD4FA8-B01C-4403-920D-BEB4F0953CD1</gtr:id><gtr:title>A conceptual framework for analysing and planning synthetic approaches to diverse lead-like scaffolds.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2418d9bf27b80a059601ddb35fc2ce1c"><gtr:id>2418d9bf27b80a059601ddb35fc2ce1c</gtr:id><gtr:otherNames>MacLellan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>doi_53d02e02ef8093f0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E0207D6-9594-4D59-A751-C6077BE1A237</gtr:id><gtr:title>Embarking on a Chemical Space Odyssey.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8caebcef9e0b56cc27e8664817ac8e98"><gtr:id>8caebcef9e0b56cc27e8664817ac8e98</gtr:id><gtr:otherNames>Chow SY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5a2fec1520dc10.96980893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DFC9533-C953-4975-AFE5-E3D734D097AA</gtr:id><gtr:title>A systematic approach to diverse, lead-like scaffolds from a,a-disubstituted amino acids.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed458e273fa6bafacc43bad3c25db685"><gtr:id>ed458e273fa6bafacc43bad3c25db685</gtr:id><gtr:otherNames>Foley DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>56b0dedac6f6b5.83067066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A95D7EDE-794F-421B-BBA0-03E96BEF3C57</gtr:id><gtr:title>Activity-Directed Synthesis with Intermolecular Reactions: Development of a Fragment into a Range of Androgen Receptor Agonists.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/479e19196646c460566c9551fd1145f6"><gtr:id>479e19196646c460566c9551fd1145f6</gtr:id><gtr:otherNames>Karageorgis G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>56b0deda597f76.91534315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F1A3F89-5465-449D-9D36-E9803504DA1C</gtr:id><gtr:title>Aminomethylhydroxylation of alkenes: Exploitation in the synthesis of scaffolds for small molecule libraries.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0797d68161979f03b128d349afe9a8a0"><gtr:id>0797d68161979f03b128d349afe9a8a0</gtr:id><gtr:otherNames>Colomer I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>56b0dedbcc92e3.55814313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32FE57A6-C43D-4A64-A8F1-E397C465E889</gtr:id><gtr:title>A unified lead-oriented synthesis of over fifty molecular scaffolds.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/379aef4304510c522d359cd5cd035ab9"><gtr:id>379aef4304510c522d359cd5cd035ab9</gtr:id><gtr:otherNames>Doveston RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>doi_55f974974a62ecd2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C82E712F-E525-4D8F-92E3-031F7EA42247</gtr:id><gtr:title>Towards the systematic exploration of chemical space.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/447725cb239c006684f637f5490d3f5a"><gtr:id>447725cb239c006684f637f5490d3f5a</gtr:id><gtr:otherNames>Dow M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>545b4384eabf03.81980622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46D58844-C85B-4D13-B735-49EFDFAF1D95</gtr:id><gtr:title>Modular, gold-catalyzed approach to the synthesis of lead-like piperazine scaffolds.</gtr:title><gtr:parentPublicationTitle>Organic letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec0dac6bfc1423c88ef584192aba005c"><gtr:id>ec0dac6bfc1423c88ef584192aba005c</gtr:id><gtr:otherNames>James T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1523-7052</gtr:issn><gtr:outcomeId>545b43842818e6.49647814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC78743D-34D5-403A-95AC-B858541168FE</gtr:id><gtr:title>A convergent rhodium-catalysed asymmetric synthesis of tetrahydroquinolines.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ec43280cfcdbacc083fc1359b4759ff"><gtr:id>1ec43280cfcdbacc083fc1359b4759ff</gtr:id><gtr:otherNames>Li HY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>545b40d55291b0.24261744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E30445F0-BAE9-4B77-8A3D-403EE31D55EF</gtr:id><gtr:title>Synthesis and Demonstration of the Biological Relevance of sp-rich Scaffolds Distantly Related to Natural Product Frameworks.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed458e273fa6bafacc43bad3c25db685"><gtr:id>ed458e273fa6bafacc43bad3c25db685</gtr:id><gtr:otherNames>Foley DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn><gtr:outcomeId>5a78ae83114ce4.25994189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B68F46AF-57D8-4348-800F-0C9FEE14C16F</gtr:id><gtr:title>Towards the realisation of lead-oriented synthesis.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac16fc2d1c29f49df9bed7c619f81a5b"><gtr:id>ac16fc2d1c29f49df9bed7c619f81a5b</gtr:id><gtr:otherNames>Doveston R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>545b40d579cff1.41993130</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D741425-4E27-494B-96EA-1A1F8E1FE2FE</gtr:id><gtr:title>Design, synthesis and decoration of molecular scaffolds for exploitation in the production of alkaloid-like libraries.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c05c88a0cc1322d482e39f89a9e89cd"><gtr:id>7c05c88a0cc1322d482e39f89a9e89cd</gtr:id><gtr:otherNames>Craven P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>56b0dedc054601.52688930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9647B2A1-A559-404E-9805-DEDE0CC15247</gtr:id><gtr:title>A divergent synthetic approach to diverse molecular scaffolds: assessment of lead-likeness using LLAMA, an open-access computational tool.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0797d68161979f03b128d349afe9a8a0"><gtr:id>0797d68161979f03b128d349afe9a8a0</gtr:id><gtr:otherNames>Colomer I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>585d7d495335e3.90752617</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7489DA48-7146-4800-8CDB-9040E89D1850</gtr:id><gtr:title>Innovative approaches to the design and synthesis of small molecule libraries.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1bdbde76fbb96c671458c550027fd0e"><gtr:id>d1bdbde76fbb96c671458c550027fd0e</gtr:id><gtr:otherNames>Nelson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>56b0dedc2aa3f6.31206031</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77C0CF36-9242-472A-A277-BDED14B5D2A5</gtr:id><gtr:title>Assessing molecular scaffolds for CNS drug discovery.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94f9ec979a8e4e2d32d150b974baf259"><gtr:id>94f9ec979a8e4e2d32d150b974baf259</gtr:id><gtr:otherNames>Mayol-Llin?s J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>5a78ae8358b174.72510642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AD685BB-EED3-44AC-9EA5-9D33EC00D557</gtr:id><gtr:title>Exploitation of the Ugi&amp;acirc;??Joulli&amp;Atilde;&amp;copy; Reaction in the Synthesis of Libraries of Drug-Like Bicyclic Hydantoins</gtr:title><gtr:parentPublicationTitle>Synthesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1bdbde76fbb96c671458c550027fd0e"><gtr:id>d1bdbde76fbb96c671458c550027fd0e</gtr:id><gtr:otherNames>Nelson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56b0dedc890546.19446837</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/J00894X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>454398F2-57A6-4959-8845-0F248CF4D5C4</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>Chemical Synthetic Methodology</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>